AltMountain

Defilade Capital Management, L.P.

Emeryville, CA · CRD 337997
Hedge fund manager

Defilade Capital Management, L.P. is an SEC-registered investment adviser based in Emeryville, CA that reports managing 1 hedge fund on Form ADV. It reports $1.5 billion in regulatory assets under management. Its private funds, of all types, hold $1.5 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +3.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +3.1% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.

Regulatory assets under management
$1.5 billionForm ADV Item 5.F
Gross assets of private funds
$1.5 billionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
7Form ADV Item 5.A
Registration
SEC-registered adviserCRD 337997
Latest Form ADV
06/26/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+3.1%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 quarters+3.1%Q1 2026 – Q2 2026
S&P 500+9.5%Same quarters, price only
13F holdings$746.9 million39 positions, 2026-06-30
$95$102$110Q1 2026Q2 202613F est. $103S&P 500 $110
QuarterEst. 13F returnS&P 500
Q2 2026+8.1%+14.8%
Q1 2026-4.7%-4.6%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 30 share positions ($598,799,890) reported by Defilade Capital Management, L.P. on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Pfizer Inc7.26%
  • Eli Lilly & Co6.72%
  • Biomarin Pharmaceutical Inc6.03%
  • Gilead Sciences Inc5.64%
  • Axsome Therapeutics Inc.5.40%
  • Amgen Inc5.21%
  • Oric Pharmaceuticals Inc5.11%
  • Ascendis Pharma A/s4.90%
  • Intuitive Surgical Inc4.88%
  • Stryker Corporation3.75%
StockValue% of 13F portfolioSharesShares vs prior quarter
Pfizer Inc$43,492,9717.26%1,524,999-13.93%
Eli Lilly & Co$40,236,3006.72%34,774-11.03%
Biomarin Pharmaceutical Inc$36,115,3206.03%601,922-11.74%
Gilead Sciences Inc$33,770,5575.64%226,572New
Axsome Therapeutics Inc.$32,336,6595.40%175,371New
Amgen Inc$31,225,0395.21%74,079New
Oric Pharmaceuticals Inc$30,610,5355.11%2,272,497+116.91%
Ascendis Pharma A/s$29,357,7184.90%128,858+35.86%
Intuitive Surgical Inc$29,220,4324.88%71,860New
Stryker Corporation$22,450,8943.75%81,524New
Vera Therapeutics Inc$21,065,2533.52%652,377New
Cogent Biosciences Inc$20,225,2733.38%631,645+60.54%
Veeva SYS Inc$19,736,2983.30%69,141-70.79%
Royalty Pharma PLC$19,387,1923.24%332,200New
Agios Pharmaceuticals Inc$18,963,0743.17%570,318+4.29%
Thermo Fisher Scientific Inc$17,867,8982.98%26,469-49.03%
Ocular Therapeutix Inc$17,453,1772.91%2,275,512+52.69%
Larimar Therapeutics Inc$15,765,5332.63%4,934,439+34.45%
Boston Scientific Corp$15,311,4602.56%350,778New
Revolution Medicines Inc$14,611,6382.44%71,186-14.05%
Solventum Corp$14,604,0752.44%165,673-47.65%
Envista Holdings Corporation$12,543,0722.09%534,430-26.40%
Olema Pharmaceuticals Inc$12,442,9562.08%1,440,157+55.73%
Evommune Inc$11,816,5331.97%1,430,573+80.37%
Eledon Pharmaceuticals Inc$8,919,1051.49%3,525,338Unchanged
Icu Med Inc$8,737,3621.46%54,435-48.50%
Enovis Corporation$7,301,6241.22%399,651-24.87%
Pacs Group Inc$6,855,0851.14%164,984-23.50%
Black Diamond Therapeutics I$3,338,2370.56%1,770,948+5.73%
Mereo Biopharma Group PLC$3,038,6200.51%7,558,756Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 8 new positions, 17 sold out, 9 increased, 11 reduced and 2 unchanged.

Number of positions (a count, not dollars)

  • New positions8
  • Increased9
  • Unchanged2
  • Reduced11
  • Sold out17

New positions

StockValueShares
Gilead Sciences Inc$33,770,557226,572
Axsome Therapeutics Inc.$32,336,659175,371
Amgen Inc$31,225,03974,079
Intuitive Surgical Inc$29,220,43271,860
Stryker Corporation$22,450,89481,524
Vera Therapeutics Inc$21,065,253652,377
Royalty Pharma PLC$19,387,192332,200
Boston Scientific Corp$15,311,460350,778

Sold out

StockValue at Jun 30, 2026Shares held then
PTC Therapeutics Inc$35,376,827433,699
Baxter Intl Inc$31,113,9821,459,380
Insmed Inc$30,049,568281,838
Zimmer Biomet Holdings Inc$27,327,204317,426
Insulet Corp$26,937,897176,932
Abbott Laboratories$25,931,496285,778
Medtronic PLC$23,727,237303,301
Elanco Animal Health Inc$21,265,009864,080
Lantheus Hldgs Inc$14,717,522132,662
Tyra Biosciences Inc$12,037,228376,870
Globus Med Inc$11,032,719139,637
Teleflex Incorporated$10,155,75880,118
Denali Therapeutics Inc$10,078,794391,866
Glaukos Corp$9,296,69566,519
Staar Surgical Co$9,241,795322,126
Crinetics Pharmaceuticals In$8,959,845239,440
Livanova PLC$8,829,282107,373

Largest increases

StockChange in sharesChangeValue nowShares now
Oric Pharmaceuticals Inc+1,224,807+116.91%$30,610,5352,272,497
Ascendis Pharma A/s+34,015+35.86%$29,357,718128,858
Cogent Biosciences Inc+238,204+60.54%$20,225,273631,645
Ocular Therapeutix Inc+785,226+52.69%$17,453,1772,275,512
Evommune Inc+637,428+80.37%$11,816,5331,430,573
Olema Pharmaceuticals Inc+515,399+55.73%$12,442,9561,440,157
Larimar Therapeutics Inc+1,264,304+34.45%$15,765,5334,934,439
Agios Pharmaceuticals Inc+23,470+4.29%$18,963,074570,318
Black Diamond Therapeutics I+95,949+5.73%$3,338,2371,770,948

Largest reductions

StockChange in sharesChangeValue nowShares now
Veeva SYS Inc-167,568-70.79%$19,736,29869,141
Thermo Fisher Scientific Inc-25,465-49.03%$17,867,89826,469
Solventum Corp-150,781-47.65%$14,604,075165,673
Icu Med Inc-51,265-48.50%$8,737,36254,435
Pfizer Inc-246,744-13.93%$43,492,9711,524,999
Eli Lilly & Co-4,312-11.03%$40,236,30034,774
Biomarin Pharmaceutical Inc-80,083-11.74%$36,115,320601,922
Envista Holdings Corporation-191,678-26.40%$12,543,072534,430
Enovis Corporation-132,294-24.87%$7,301,624399,651
Revolution Medicines Inc-11,641-14.05%$14,611,63871,186
Pacs Group Inc-50,691-23.50%$6,855,085164,984

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌​‌⁠